Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
812 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Multiple Sclerosis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H1 2017, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape. Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 9, 30, 32, 1, 168, 34 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 47 and 2 molecules, respectively. Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 9 Multiple Sclerosis - Overview 10 Multiple Sclerosis - Therapeutics Development 11 Multiple Sclerosis - Therapeutics Assessment 48 Multiple Sclerosis - Companies Involved in Therapeutics Development 70 Multiple Sclerosis - Drug Profiles 160 Multiple Sclerosis - Dormant Projects 746 Multiple Sclerosis - Discontinued Products 763 Multiple Sclerosis - Product Development Milestones 766 Appendix 778
List of Tables
Number of Products under Development for Multiple Sclerosis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Products under Development by Companies, H1 2017 (Contd..7), H1 2017 Products under Development by Companies, H1 2017 (Contd..8), H1 2017 Products under Development by Companies, H1 2017 (Contd..9), H1 2017 Products under Development by Companies, H1 2017 (Contd..10), H1 2017 Products under Development by Companies, H1 2017 (Contd..11), H1 2017 Products under Development by Companies, H1 2017 (Contd..12), H1 2017 Products under Development by Companies, H1 2017 (Contd..13), H1 2017 Products under Development by Companies, H1 2017 (Contd..14), H1 2017 Products under Development by Companies, H1 2017 (Contd..15), H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Multiple Sclerosis - Pipeline by 2-BBB Medicines BV, H1 2017 Multiple Sclerosis - Pipeline by 4D Pharma PLC, H1 2017 Multiple Sclerosis - Pipeline by AB Science SA, H1 2017 Multiple Sclerosis - Pipeline by AbbVie Inc, H1 2017 Multiple Sclerosis - Pipeline by Abion Inc, H1 2017 Multiple Sclerosis - Pipeline by Ablynx NV, H1 2017 Multiple Sclerosis - Pipeline by Abzena Plc, H1 2017 Multiple Sclerosis - Pipeline by Acorda Therapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Actelion Ltd, H1 2017 Multiple Sclerosis - Pipeline by Adamas Pharmaceuticals Inc, H1 2017 Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H1 2017 Multiple Sclerosis - Pipeline by Adhaere Pharmaceuticals Inc, H1 2017 Multiple Sclerosis - Pipeline by Aegis Therapeutics LLC, H1 2017 Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H1 2017 Multiple Sclerosis - Pipeline by AiCuris GmbH & Co KG, H1 2017 Multiple Sclerosis - Pipeline by Alkermes Plc, H1 2017 Multiple Sclerosis - Pipeline by Allergan Plc, H1 2017 Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc, H1 2017 Multiple Sclerosis - Pipeline by Alvotech Iceland, H1 2017 Multiple Sclerosis - Pipeline by Amarna Therapeutics BV, H1 2017 Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp, H1 2017 Multiple Sclerosis - Pipeline by Antisense Therapeutics Ltd, H1 2017 Multiple Sclerosis - Pipeline by Aphios Corp, H1 2017 Multiple Sclerosis - Pipeline by Apitope International NV, H1 2017 Multiple Sclerosis - Pipeline by ARA Healthcare Pvt Ltd, H1 2017 Multiple Sclerosis - Pipeline by Argos Therapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals LLC, H1 2017 Multiple Sclerosis - Pipeline by Artielle ImmunoTherapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Arven Ilac, H1 2017 Multiple Sclerosis - Pipeline by Asterias Biotherapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by AstraZeneca Plc, H1 2017 Multiple Sclerosis - Pipeline by Atara Biotherapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Athersys Inc, H1 2017 Multiple Sclerosis - Pipeline by Atlantic Bio Sci LLC, H1 2017 Multiple Sclerosis - Pipeline by Axxam SpA, H1 2017 Multiple Sclerosis - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017 Multiple Sclerosis - Pipeline by BioApex sro, H1 2017 Multiple Sclerosis - Pipeline by Biocad, H1 2017 Multiple Sclerosis - Pipeline by Biocon Ltd, H1 2017 Multiple Sclerosis - Pipeline by Biogen Inc, H1 2017 Multiple Sclerosis - Pipeline by BioHealthonomics Inc, H1 2017 Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H1 2017 Multiple Sclerosis - Pipeline by Bionovis SA, H1 2017 Multiple Sclerosis - Pipeline by Bionure Farma SL, H1 2017 Multiple Sclerosis - Pipeline by Biovista Inc, H1 2017 Multiple Sclerosis - Pipeline by Bolder Biotechnology Inc, H1 2017 Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Bristol-Myers Squibb Company, H1 2017 Multiple Sclerosis - Pipeline by CASI Pharmaceuticals Inc, H1 2017 Multiple Sclerosis - Pipeline by Catalyst Pharmaceuticals Inc, H1 2017 Multiple Sclerosis - Pipeline by Celgene Corp, H1 2017 Multiple Sclerosis - Pipeline by Cell Cure Neurosciences Ltd, H1 2017 Multiple Sclerosis - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017 Multiple Sclerosis - Pipeline by Cinnagen Co, H1 2017 Multiple Sclerosis - Pipeline by Cognosci Inc, H1 2017 Multiple Sclerosis - Pipeline by Coherus BioSciences Inc, H1 2017 Multiple Sclerosis - Pipeline by Commence Bio Inc, H1 2017 Multiple Sclerosis - Pipeline by Compugen Ltd, H1 2017 Multiple Sclerosis - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017 Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc, H1 2017 Multiple Sclerosis - Pipeline by CuraVac Inc, H1 2017 Multiple Sclerosis - Pipeline by Cyxone AB, H1 2017 Multiple Sclerosis - Pipeline by DanDrit Biotech A/S, H1 2017 Multiple Sclerosis - Pipeline by Denceptor Therapeutics Ltd, H1 2017 Multiple Sclerosis - Pipeline by Dimerix Bioscience Pty Ltd, H1 2017 Multiple Sclerosis - Pipeline by Eisai Co Ltd, H1 2017 Multiple Sclerosis - Pipeline by Eli Lilly and Company, H1 2017 Multiple Sclerosis - Pipeline by Evgen Pharma Plc, H1 2017 Multiple Sclerosis - Pipeline by Evotec AG, H1 2017 Multiple Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Multiple Sclerosis - Pipeline by Flex Pharma Inc, H1 2017 Multiple Sclerosis - Pipeline by Forward Pharma A/S, H1 2017 Multiple Sclerosis - Pipeline by FPRT Bio Inc, H1 2017 Multiple Sclerosis - Pipeline by Gemac SA, H1 2017 Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017 Multiple Sclerosis - Pipeline by GeNeuro SA, H1 2017 Multiple Sclerosis - Pipeline by Genzyme Corp, H1 2017 Multiple Sclerosis - Pipeline by GlaxoSmithKline Plc, H1 2017 Multiple Sclerosis - Pipeline by Glialogix Inc, H1 2017 Multiple Sclerosis - Pipeline by Hansa Medical AB, H1 2017 Multiple Sclerosis - Pipeline by Harbor Therapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Humabs BioMed SA, H1 2017 Multiple Sclerosis - Pipeline by Hutchison China MediTech Ltd, H1 2017 Multiple Sclerosis - Pipeline by Immune Response BioPharma Inc, H1 2017 Multiple Sclerosis - Pipeline by Immune Therapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Immungenetics AG, H1 2017 Multiple Sclerosis - Pipeline by Immunwork Inc, H1 2017 Multiple Sclerosis - Pipeline by Inception Sciences Inc, H1 2017 Multiple Sclerosis - Pipeline by Innate Immunotherapeutics Ltd, H1 2017 Multiple Sclerosis - Pipeline by Inovio Pharmaceuticals Inc, H1 2017 Multiple Sclerosis - Pipeline by Io Therapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Jyant Technologies Inc, H1 2017 Multiple Sclerosis - Pipeline by Kadimastem Ltd, H1 2017 Multiple Sclerosis - Pipeline by Kadmon Corp LLC, H1 2017 Multiple Sclerosis - Pipeline by KAHR medical Ltd, H1 2017 Multiple Sclerosis - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017 Multiple Sclerosis - Pipeline by Kancera AB, H1 2017 Multiple Sclerosis - Pipeline by Karo Pharma AB, H1 2017 Multiple Sclerosis - Pipeline by Karyopharm Therapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017 Multiple Sclerosis - Pipeline by KPI Therapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017 Multiple Sclerosis - Pipeline by Lead Discovery Center GmbH, H1 2017 Multiple Sclerosis - Pipeline by LFB SA, H1 2017 Multiple Sclerosis - Pipeline by Lipocure Ltd, H1 2017 Multiple Sclerosis - Pipeline by MacroGenics Inc, H1 2017 Multiple Sclerosis - Pipeline by Mapi Pharma Ltd, H1 2017 Multiple Sclerosis - Pipeline by Marathon Pharmaceuticals LLC, H1 2017 Multiple Sclerosis - Pipeline by MedAnnex Ltd, H1 2017 Multiple Sclerosis - Pipeline by MedDay SA, H1 2017 Multiple Sclerosis - Pipeline by Medestea Research & Production SpA, H1 2017 Multiple Sclerosis - Pipeline by MedImmune LLC, H1 2017 Multiple Sclerosis - Pipeline by Merck KGaA, H1 2017 Multiple Sclerosis - Pipeline by Meta-IQ ApS, H1 2017 Multiple Sclerosis - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017 Multiple Sclerosis - Pipeline by Mitotech SA, H1 2017 Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017 Multiple Sclerosis - Pipeline by Mochida Pharmaceutical Co Ltd, H1 2017 Multiple Sclerosis - Pipeline by MorphoSys AG, H1 2017 Multiple Sclerosis - Pipeline by Mount Tam Biotechnologies Inc, H1 2017 Multiple Sclerosis - Pipeline by Neuralstem Inc, H1 2017 Multiple Sclerosis - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017 Multiple Sclerosis - Pipeline by Neurofx Inc, H1 2017 Multiple Sclerosis - Pipeline by Neuronax SAS, H1 2017 Multiple Sclerosis - Pipeline by New World Laboratories Inc, H1 2017 Multiple Sclerosis - Pipeline by Novartis AG, H1 2017 Multiple Sclerosis - Pipeline by Nuevolution AB, H1 2017 Multiple Sclerosis - Pipeline by Numab Innovation AG, H1 2017 Multiple Sclerosis - Pipeline by Ogeda SA, H1 2017 Multiple Sclerosis - Pipeline by Omeros Corp, H1 2017 Multiple Sclerosis - Pipeline by OncoImmune Inc, H1 2017 Multiple Sclerosis - Pipeline by Opexa Therapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Oryzon Genomics SA, H1 2017 Multiple Sclerosis - Pipeline by OSE Immunotherapeutics, H1 2017 Multiple Sclerosis - Pipeline by Pangen Biotech Inc., H1 2017 Multiple Sclerosis - Pipeline by Parvus Therapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Pfenex Inc, H1 2017 Multiple Sclerosis - Pipeline by Pfizer Inc, H1 2017 Multiple Sclerosis - Pipeline by Pharmaxis Ltd, H1 2017 Multiple Sclerosis - Pipeline by ProNoxis AB, H1 2017 Multiple Sclerosis - Pipeline by Prothena Corp Plc, H1 2017 Multiple Sclerosis - Pipeline by Quimatryx SL, H1 2017 Multiple Sclerosis - Pipeline by ReceptoPharm Inc, H1 2017 Multiple Sclerosis - Pipeline by RedHill Biopharma Ltd, H1 2017 Multiple Sclerosis - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017 Multiple Sclerosis - Pipeline by Regenesance BV, H1 2017 Multiple Sclerosis - Pipeline by Renovo Neural Inc, H1 2017 Multiple Sclerosis - Pipeline by Resverlogix Corp, H1 2017 Multiple Sclerosis - Pipeline by ReveraGen BioPharma Inc, H1 2017 Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals Inc, H1 2017 Multiple Sclerosis - Pipeline by Rock Creek Pharmaceuticals Inc, H1 2017 Multiple Sclerosis - Pipeline by Rodos BioTarget GmbH, H1 2017 Multiple Sclerosis - Pipeline by SanBio Inc, H1 2017 Multiple Sclerosis - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2017 Multiple Sclerosis - Pipeline by Sareum Holdings Plc, H1 2017 Multiple Sclerosis - Pipeline by Senju Pharmaceutical Co Ltd, H1 2017 Multiple Sclerosis - Pipeline by Sorrento Therapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Spherium Biomed SL, H1 2017 Multiple Sclerosis - Pipeline by Symic Biomedical Inc, H1 2017 Multiple Sclerosis - Pipeline by Synthon Holdings BV, H1 2017 Multiple Sclerosis - Pipeline by Teikoku Pharma USA Inc, H1 2017 Multiple Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017 Multiple Sclerosis - Pipeline by TikoMed AB, H1 2017 Multiple Sclerosis - Pipeline by Tiziana Life Sciences Plc, H1 2017 Multiple Sclerosis - Pipeline by Toleranzia AB, H1 2017 Multiple Sclerosis - Pipeline by Topas Therapeutics GmbH, H1 2017 Multiple Sclerosis - Pipeline by TxCell SA, H1 2017 Multiple Sclerosis - Pipeline by Vaccinex Inc, H1 2017 Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H1 2017 Multiple Sclerosis - Pipeline by Vicore Pharma AB, H1 2017 Multiple Sclerosis - Pipeline by viDA Therapeutics Inc, H1 2017 Multiple Sclerosis - Pipeline by Virogenomics BioDevelopment Inc, H1 2017 Multiple Sclerosis - Pipeline by VivaCell Biotechnology Espana SL, H1 2017 Multiple Sclerosis - Pipeline by Xenetic Biosciences Inc, H1 2017 Multiple Sclerosis - Pipeline by XL-protein GmbH, H1 2017 Multiple Sclerosis - Pipeline by Yungjin Pharm Co Ltd, H1 2017 Multiple Sclerosis - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..1), H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..2), H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..3), H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..4), H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..5), H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..6), H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..7), H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..8), H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..9), H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..10), H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..11), H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..12), H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..13), H1 2017 Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..14), H1 2017 Multiple Sclerosis - Discontinued Products, H1 2017 Multiple Sclerosis - Discontinued Products, H1 2017 (Contd..1), H1 2017 Multiple Sclerosis - Discontinued Products, H1 2017 (Contd..2), H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
